CoChat

Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease

Pineda‐Roman, Mauricio, Bolejack, Vanessa, Arzoumanian, Varant, Anaissie, Elias, Van Rhee, Frits, Zangari, Maurizio, Walker, Ron, Hollmig, Klaus, Shaughnessy, John D., Epstein, Joshua, Krishna, Somashekar, Crowley, John, Barlogie, Bart · 2007 · British Journal of Haematology
Cited by 66

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: Complete response (CR) is still considered an important surrogate marker for outcome in multiple myeloma (MM). Long‐term survival after transplantation, however, has been observed in a substantial proportion of patients who never achieved CR. The tandem transplant trial, Total Therapy 2, enrolled 668 patients, who were randomised up‐front to thalidomide (THAL) or no THAL; 56 patients were identified as having had, for at least 6 months prior to initiation of therapy, monoclonal gammopathy of undetermined significance (MGUS,n = 21), smouldering MM (SMM,n = 22) or solitary plasmacytoma of bone (SPC,n = 13). The clinical characteristics and outcomes of patients with such ‘evolved’ MM (E‐MM) and of those with ‘unknown’ prior history (U‐MM) were compared. Fewer patients with MGUS/SMM‐E‐MM had anaemia or renal failure; CR was lower (22% vs. 48%) but 4‐year estimates of event‐free survival (54% vs. 56% with U‐MM) and overall survival (65% vs. 70% with U‐MM) were similar to those with SPC‐E‐MM or U‐MM. In the latter group, achieving CR was associated with prolonged survival. In comparison with U‐MM, E‐MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U‐MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2006.06441.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 66

Metadata

Authors
Pineda‐Roman, M., Bolejack, V., Arzoumanian, V., Anaissie, E., Van Rhee, F., Zangari, M., Walker, R., Hollmig, K., Shaughnessy, J. D., Epstein, J., Krishna, S., Crowley, J., & Barlogie, B.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2006-12-08
Volume
136
Issue
3
Pages
393-399
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1978850023
Cited by
66
References
7
FWCI
4.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. https://app.cochat.ai/papers/10.1111/j.1365-2141.2006.06441.x
The paper
Pineda‐Roman, M., Bolejack, V., Arzoumanian, V., Anaissie, E., Van Rhee, F., Zangari, M., Walker, R., Hollmig, K., Shaughnessy, J. D., Epstein, J., Krishna, S., Crowley, J., & Barlogie, B. (2007). Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2006.06441.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.